# A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia

> **NCT05929807** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Ascendis Pharma Growth Disorders A/S** · enrollment: 140 (estimated)

## Conditions studied

- Achondroplasia

## Interventions

- **DRUG:** TransCon CNP

## Key facts

- **NCT ID:** NCT05929807
- **Lead sponsor:** Ascendis Pharma Growth Disorders A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-06-21
- **Primary completion:** 2039-01
- **Final completion:** 2039-03
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05929807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05929807, "A Clinical Trial to Investigate Long-term Safety, Tolerability, and Efficacy of Weekly Subcutaneous Doses With TransCon CNP in Children and Adolescents With Achondroplasia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05929807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*